en ENGLISH
ISSN: 1734-1558
Forum Ortodontyczne / Orthodontic Forum
Bieżący numer Archiwum O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
SCImago Journal & Country Rank
3/2020
vol. 16
 
Poleć ten artykuł:
Udostępnij:
więcej
 
 
Artykuł przeglądowy

Bisfosfoniany a leczenie ortodontyczne - przegląd piśmiennictwa

Anna Marzec
1
,
Liwia Elżbieta Minch
1

1.
Prywatna praktyka/Private practice
Forum Ortod 2020; 16 (3): 239-52
Data publikacji online: 2020/11/10
Plik artykułu:
- Marzec.pdf  [2.26 MB]
Pobierz cytowanie
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 
1. Bartzela T, Türp JC, Motschall E, Maltha JC. Medication effects on the rate of orthodontic tooth movement: A systematic literature review. Am J Orthod Dentofacial Orthop 2009; 135: 16-26.
2. Lotwala RB, Greenlee GM, Ott SM, Hall SH, Huang GJ. Bisphosphonates as a risk factor for adverse orthodontic outocomes. A retrospective cohort study. Am J Orthod Dentofacial Orthop 2012; 142: 625-34.
3. Krieger E, d‘Hoedt B, Scheller H, Jacobs C, Walter C, Wehrbein H. Orthodontic treatment of patients medicated with bisphosphonates—a clinical case report. J Orofac Orthop 2013; 74: 28-39.
4. Zahrowski JJ. Optimizing orthodontic treatment in patients taking bisphosphonates for osteoporosis. Am J Orthod Dentofacial Orthop 2009; 135: 361-74.
5. Czyżykowski R, Krakowska M, Potemski P. Bisphosphonates for the treatment of patients with cancer. Oncol Clin Pract 2017; 13: 268-74.
6. Watts NB. Treatment of osteoporosis with bisphosphonates. EMCNA 1998; 27: 419-39.
7. Putranto R, Oba Y, Kaneko K, Shioyasono A, Moriyama K. Effects of bisphosphonates on root resorption and cytokine expression during experimental tooth movement in rats. Orthod Waves 2008; 67: 141-9.
8. Drake M, Clarke B, Khosla S. Bisphosphonates: Mechanism of Action and Role in Clinical Practice. Mayo Clinic 2008; 83: 1032-45.
9. Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of Bisphosphonates. Br J Clin Pharmacol 2019; 85: 1052-62.
10. Tosteson ANA, Grove MR, Hammond CS, Moncur MM, Ray T, Hebert GM, Pressman AR, Ettinger B. Early discontinuation of treatment for osteoporosis. Am J Med 2003; 115: 209-16.
11. Woszuk K, Lisowska B, Prusinowska A. Alendronian, ryzedronian i ibandronian w leczeniu osteoporozy. Geriatria 2012; 6: 1-10.
12. Drosik K, Krzakowski M, Jarosz J, Kraj M, Krzemieniecki K, Pieńkowski T, Utracka-Hutka B, Jassem J, Szczylik C, Wojtukiewicz M, Ziobro M. Bisfosfoniany w zapobieganiu i kontroli zdarzeń kostnych u chorych z przerzutami nowotworów złośliwych do kości. Onkol Prakt Klin Edu 2006; 4: 152-64.
13. Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008; 139: 1674-7.
14. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008; 44: 857-69.
15. Jeong HG, Hwang JJ, Lee JH, Kim YH, Na JY, Han SS. Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates. Imaging Sci Dent 2017; 47: 45-50.
16. Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 2015; 44: 568-85.
17. Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007; 21: 1545-8.
18. Senel FC, Kadioglu Duman M, Muci E, Cankaya M, Pampu AA, Ersoz S, Gunhan O. Jaw bone changes in rats after treatment with zoledronate and pamidronate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 109: 385-91.
19. Salvatore L. Ruggiero. Bisphosphonate‐related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci 2011; 1218: 38-46.
20. Zahrowski J. Bisphosphonate treatment: An orthodontic concern calling for a proactive approach. Am J Orthod Dentofacial Orthop 2007; 131: 311-20.
21. Ghoneima AA, Allam ES, Zunt SL, Windsor LJ. Bisphosphonates treatment and orthodontic considerations. Orthod Craniofac Res 2010; 13: 1-10.
22. Dental management of patients receiving oral bisphosphonate therapy. Expert panel recommendations. J Am Dent Assoc 2006; 137: 1144-50.
23. Litwiniuk M, Kopczynski Z. Przydatność markerów obrotu kostnego w rozpoznaniu i monitorowaniu przebiegu leczenia przerzutów nowotworowych do kości. Cotemp Oncol 2002; 7: 384.
24. Marx RE, Cillo JE, Ulloa JJ. Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment. Int J Oral Maxillofac Surg 2008; 65: 2397-410.
25. Flichy-Fernández AJ, Alegre-Domingo T, González-Lemonnier S, Balaguer-Martínez J, Peñarrocha-Diago M, Peñarrocha-Diago M, Jiménez-Soriano Y, Peñarrocha-Oltra D, Bagan JV. Study of serum CTX in 50 oral surgical patients. Med Oral Patol Oral Cir Bucal. 2012; 17: 367-70.
26. Smidt A, Lipovetsky-Adler M, Sharon E. Forced eruption as an alternative to tooth extraction in long-term use of oral bisphosphonates. J Am Dent Assoc. 2012; 143: 1303-12.
27. Morita H, Imai Y, Yoneda M, Hirofuji T. Applying orthodontic tooth extrusion in a patient treated with bisphosphonate and irradiation: a case report. Spec Care Dentist 2016; 37: 43-6.
28. Bishop N. Characterising and treating osteogenesis imperfecta. Early Hum Dev 2010; 86: 743–6.
29. O’Connell AC, Marini JC. Evaluation of oral problems in an osteogenesis imperfecta population. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 87: 189-96.
30. Kindelan J, Tobin M, Roberts-Harry D, Loukota RA. Clinical section: Orthodontic and orthognathic management of a patient with osteogenesis imperfecta and dentinogenesis imperfecta: A case report. J Orthod 2004; 30: 291-6.
31. Kamoun-Goldrat A, Ginisty D, Merrer M. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci 2008; 116: 195-8.
32. Malmgren B, Norgren S. Dental aberrations in children and adolescents with osteogenesis imperfecta. Acta Odontol Scand 2002; 60: 65-71.
33. Bhatt RN, Munns CM, Hibbert SA, Blinkhorn AS. Baseline survey on the oral health of children on intravenous bisphosphonates. The University of Sydney 2010.
34. Schwartz S, Tsipouras P. Oral findings in osteogenesis imperfecta. Oral Surg Oral Med Oral Pathol 1984; 57: 161-7.
35. Bhatt RN, Hibbert SA, Munns CF. The use of bisphosphonates in children: Review of the literature and guidelines for dental management. Aust Dent J 2014; 59: 9-19.
36. Lam DK, Sándor GKB, Holmes HI, Evans AW, Clokie CM. Bisphosphonate associated osteonecrosis of the jaws: a review for dentists. J Can Dent Assoc 2007; 73: 171-6.
37. Duarte NT, Rech BO, Martins IG, Franco JB, Ortega KL. Can children be affected by bisphosphonate-related osteonecrosis of the jaw? A systematic review. Int J Oral Maxillofac Surg 2019; 49: 183-91.
38. Ngan KK, Bowe J, Goodger N. The risk of bisphosphonate-related osteonecrosis of the jaw in children. A case report and literature review. Dent Update 2013; 40: 733-8.
39. Schwartz S, Joseph C, Iera D, Vu DD. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: A case series. J Can Dent Assoc 2008; 74: 537-42.
40. Cheng A, Sambrook P, Goss A. Use of bisphosphonates in children. Aust Dent J 2014; 59: 405.
41. Verna C, Dalstra M, Melsen B. The rate and the type of orthodontic tooth movement is influenced by bone turnover in a rat model. Eur J Orthod 2000; 22: 343-52.
42. Choi J, Baek SH, Lee JI, Chang YI. Effects of clodronate on early alveolar bone remodeling and root resorption related to orthodontic forces: A histomorphometric analysis. Am J Orthod Dentofacial Orthop 2010; 138: 548e1-8.
43. Fujimura Y, Kitaura H, Yoshimatsu M, Eguchi T, Kohara H, Morita Y, Yoshida N. Influence of bisphosphonates on orthodontic tooth movement in mice. Eur J Orthod 2009; 31: 572-7.
44. Adachi H, Igarashi K, Mitani H, Shinoda H. Effects of Topical Administration of a Bisphosphonate (Risedronate) on Orthodontic Tooth Movements in Rats. J Dent Res 1994; 73: 1478-86.
45. Kaipatur N, Wu Y, Adeeb S, Stevenson T, Major P, Doschak M. Impact of bisphosphonate drug burden in alveolar bone during orthodontic tooth movement in a rat model: A pilot study. Am J Orthod Dentofacial Orthop 2013; 144: 557-67.
46. Rinchuse DJ, Rinchuse DJ, Sosovicka MF, Robison JM, Pendleton R. Orthodontic treatment of patients using bisphosphonates: A report of 2 cases. Am J Orthod Dentofacial Orthop 2007; 131: 321-6.
47. Lotwala RB, Greenlee GM, Ott SM, Hall SH, Huang GJ. Bisphosphonates as a risk factor for adverse orthodontic outcomes: A retrospective cohort study. Am J Orthod Dentofacial Orthop 2012; 142: 625-34.
48. Cuairán C, Campbell P, Kontogiorgos E, Taylor R, Melo A, Buschang P. Local application of zoledronate enhances miniscrew implant stability in dogs. Am J Orthod Dentofacial Orthop 2014; 145: 737-49.
49. Dewachi Z, Obaidi H. The Effect of local Application of Zoledronate on the level of Interleukin 1Beta Around Orthodontic Miniscrew in Control Diabetic Sample (Experimental Study on Dogs). Int J Enhanced Res Sci Technol Eng 2015; 4: 74-81.
50. Graham JW. Bisphosphonates and orthodontics: Clinical implications. J Clin Orthod 2006; 40: 425-8.
51. Jeffcoat MK. Safety of oral bisphosphonates: Controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006; 21: 349-53.
52. Ortega AJ, Campbell PM, Hinton R, Naidu A, Buschang PH. Local application of zoledronate for maximum anchorage during space closure. Am J Orthod Dentofacial Orthop 2012; 142: 780-91.
53. Igarashi K, Mitani H, Adachi H, Shinoda H. Anchorage and retentive effects of a bisphosphonate (AHBuBP) on tooth movements in rats. Am J Orthod Dentofacial Orthop 1994; 106: 279-89.
54. Liu L. Effects of local administration of clodronate on orthodontic tooth movement and root resorption in rats. Eur J Orthod 2004; 26: 469-73.
55. Justus R. Prevention of external apical root resorption during orthodontic treatment. Clin Dent Rev 2018; 2: 23.
56. Igarashi K, Adachi H, Mitani H, Shinoda H. Inhibitory Effect of the Topical Administration of a Bisphosphonate (Risedronate) on Root Resorption Incident to Orthodontic Tooth Movement in Rats. J Dent Res 1996; 75: 1644-9.
57. Alatli I, Huitenby K, Hammarstrom L. Disturbances of cementum formation induced by single injection of l-hydroxyethylidene- 1,l -bisphosphonate (HEBF') in rats: Light and scanning electron microscopic studies. Scand J Dent Res 1994; 102: 260-8.
58. El-Bialy T, El-Shamy I, Graber TM. Repair of orthodontically induced root resorption by ultrasound in humans. Am J Orthod Dentofacial Orthop 2004; 126: 186-93.
59. Lee K, Sugiyama H, Imoto S, Tanne K. Effects of Bisphosphonate on the Remodeling of Rat Sagittal Suture after Rapid Expansion. Angle Orthod 2001; 71: 265-73.
This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.